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a  b  s  t  r  a  c  t
The  management  of  spondyloarthritis  is  challenging  and  has  changed  with the  development  of new
concepts  and  treatments.
Objective: To develop  practice  guidelines  for the  everyday  management  of  patients  with spondyloarthritis
(including  psoriatic  arthritis),  by  updating  previous  national  and  international  recommendations,  based
on a review  of  recently  published  data.
Methods:  A  task  force and  a  multidisciplinary  literature  review  group  were  established.  The  task  force
identiﬁed  the  issues  that  remained  unresolved.  Based  on  existing  recommendations  and recent  publica-
tions,  the task  force  developed  practice  guidelines,  which  were  revised  by  the  literature  review  group
and  graded  according  to  AGREE.hysiotherapy
SAIDs
NF antagonists
Results:  Practice  guidelines  for  the  management  of  spondyloarthritis  are reported.  After a review  of the
general  diagnostic  principles,  30  practice  guidelines  are  given:  5 on  general  principles,  4 on  the manage-
ment  strategy,  5 on  non-pharmacological  treatments,  7 on  conventional  pharmacological  treatments,  6
on biotherapies,  and  3 on surgical  treatments  and  follow-up.
Conclusion:  The  updated  practice  guidelines  reported  here  constitute  a global  framework  that  can  guide
physicians  in the  everyday  management  of  spondyloarthritis.
nc¸ ais©  2013  Société  fra
. Introduction: the setting
The term “spondyloarthritis” designates an array of rheumatic
iseases responsible for a variety of clinical pictures. The ﬁeld of
pondyloarthritis has undergone major changes in recent years,
egarding not only the nosology and classiﬁcation, but also the
nvestigations (most notably imaging studies) and, above all,
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treatments, with the introduction of TNF antagonists. Conse-
quently, the French Society for Rheumatology (Société franc¸ aise de
rhumatologie, [SFR]) has developed practice guidelines for spondy-
loarthritis based on the previous recommendations and recently
published data.
2. MethodologyThe overall objective is to develop practice guidelines for
spondyloarthritis based on an update and French adaptation of
existing recommendations issued by the ASAS/EULAR and ASAS
(Assessment in Spondyloarthritis International Society) [1,2]. To
lsevier Masson SAS. All rights reserved.
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Table 1
Suggested terminology for describing the clinical phenotype of patients with
spondyloarthritis [16].
Axial spondyloarthritis
Radiographica (including ankylosing spondylitis)
Non-radiographica
Spondyloarthritis with peripheral joint involvement
Erosivea
Non-erosiveaD. Wendling et al. / Join
his end, we followed both the general principles put forward in
GREE II [3] and EULAR rules for developing recommendations [4].
Our starting point was the set of ASAS/EULAR recommendations
or managing ankylosing spondylitis [1] and the updated recom-
endations on TNF antagonist therapy in spondyloarthritis [2],
ith the corresponding literature reviews [5,6], recommendations
n psoriatic arthritis [7,8], and French recommendations on TNF
ntagonist therapy, speciﬁcally in spondyloarthritis and psoriatic
rthritis [9] and generally in rheumatic diseases [10]. We  also took
nto account recent recommendations on targeted treatments [11],
ith their underlying evidentiary base [12].
We constituted a task force whose coordinator was  a project
irector appointed by the SFR (DW). This group was com-
osed of rheumatologists considered by the SFR to be experts
n spondyloarthritis, a rheumatologist specialized in methodology
nd epidemiology, and a patient with spondyloarthritis who was a
ember of a patient self-help organization. A systematic literature
eview was conducted by two university-hospital rheumatologists
ho were trained in literature reviews (CL, JP). Articles published
etween January 1, 2010, and June 17, 2013, were retrieved using
ppropriate key terms to search PubMed-Medline, Cochrane, and
mbase. In addition, a manual search of article reference lists and
ULAR and ACR meeting abstracts was performed. The level of
vidence of each publication was assessed. In preliminary work,
he task force identiﬁed unresolved issues and points requiring
pdates. A physical meeting was held for presentation of the lit-
rature review data, discussion among experts, and development
f the practice guidelines. Subsequently, the practice guidelines
ere reviewed by the same experts for validation and rating of the
evel of agreement, from which the grade of each practice guideline
as determined. Finally, the practice guidelines were submitted to
 group of reviewers designated by the task force and described
elow. The ﬁnal version was modiﬁed based on the comments by
oth groups.
. Target of the practice guidelines
These practice guidelines are intended for physicians and
ther healthcare professionals involved in managing patients with
pondyloarthritis. However, their global scope makes them chieﬂy
elevant to rheumatologists. A document intended for patients will
e developed.
. Conceptual deﬁnition of spondyloarthritides: the
iseases involved
These practice guidelines are relevant to all adults who  meet
urrent classiﬁcation criteria. These criteria have evolved over time,
n particular, with the introduction of new imaging studies, most
otably magnetic resonance imaging (MRI) of the sacroiliac joints
sed for diagnostic purposes. The ASAS has issued classiﬁcation
riteria for axial [13] and peripheral [14] forms of spondyloarthritis.
hus, these practice guidelines apply overall to patients meeting
SAS criteria, as well as to patients meeting other criteria sets, such
s those developed by Amor et al. and the ESSG [15], whose validity
emains undeniable.
. Terminology
The term “spondyloarthritis” encompasses several disease
henotypes, including the classical nosological entities (ankylos-
ng spondylitis, psoriatic arthritis, reactive arthritis, enteropathic
rthropathies, and undifferentiated spondylarthropathies). Thus,
he term used to designate all these diseases is “spondyloarthritis”
16], which has replaced the term “spondylarthropathy” (Table 1).Spondyloarthritis with peripheral enthesitisa
a Add any concomitant extraarticular manifestations to better characterize the
phenotype (with psoriasis, Crohn’s disease, ulcerative colitis, and anterior uveitis).
Non-radiographic axial spondyloarthritis is a new concept indi-
vidualized by current criteria [17]. This classiﬁcation incorporates,
among other diseases, psoriatic arthritis with its various pheno-
typic presentations, which are forms of spondyloarthritis. Thus,
these practice guidelines apply to psoriatic arthritis manifesting
as axial disease, peripheral joint disease, or peripheral enthesitis.
6. Diagnosis
The early diagnosis of spondyloarthritis is challenging and rests
on a combination of ﬁndings from the medical history, physical
examination, laboratory tests, and imaging studies, on which the
expert can base an opinion. The task force emphasizes the impor-
tance of strict adherence to the deﬁnitions of the items in the
criteria sets, to ensure their validity. This requirement applies also
to the imaging criteria, most notably, the MRI  criteria. The risk of
overdiagnosis should be acknowledged and taken into account [18].
At present, the imaging study sign used to establish the diag-
nosis is an MRI  ﬁnding of subchondral bone marrow edema in
the sacroiliac joints, on at least two  consecutive sections if a sin-
gle topographic zone is abnormal; or of bone marrow edema in
at least two  different periarticular sites. To be valid, these abnor-
malities must be unequivocal and sufﬁciently extensive to rule out
a non-speciﬁc lesion or artefact, particularly of a vascular nature
[19]. It is important to be aware, however, that these ﬁndings are
inconsistent: some patients with a deﬁnite diagnosis of spondy-
loarthritis and clinical or laboratory evidence of disease activity
have normal MRI  ﬁndings. MRI  of the spine can beneﬁt the ini-
tial management of the patient, not only to rule out differential
diagnoses (e.g., benign or malignant spinal tumors, infections of
the disks and vertebras, or inﬂammatory disk disease), but also to
detect other lesion types that suggest spondyloarthritis and may
therefore support the diagnosis. Thus, the presence of a large num-
ber of “inﬂammatory” signals or of fatty involution at the vertebral
corners lends some support to the possibility of spondyloarthritis
when combined with back pain, particularly in younger patients
with involvement of a large number of vertebras. Nevertheless,
these MRI  abnormalities can be found in non-speciﬁc low back pain,
vertebral malignancies, and even healthy individuals and, when
isolated, are consequently not sufﬁcient to establish a diagnosis
of spondyloarthritis. Recent studies have shown that repeating the
MRI  scans fails to beneﬁt the diagnosis. Finally, the task force points
out that criteria intended solely for classiﬁcation purposes should
be used for diagnostic purposes only with the utmost caution.
The work presented here does not apply to pediatric spondy-
loarthritis, since the ASAS criteria are not relevant to children, in
whom the clinical presentation is often different from that seen
in adults. In addition, the therapeutic trials referred to in these
practice guidelines were conducted only in adults.
7. Practice guidelinesThe strength of the practice guidelines (based on the level of
evidence) and the level of agreement among experts (rated from
0 [strongly disagrees] to 10 [strongly agrees]) are given for each
8 t Bone
p
p
•
•
•
•
7
7 D. Wendling et al. / Join
ractice guideline. Strength was graded according to standard
ractice:
A: guideline based on level 1 evidence (meta-analysis of ran-
domized controlled trials or at least one randomized controlled
trial);
B: guideline based on level 2 evidence (at least one nonrandom-
ized controlled trial or quasi-experimental study) or extrapolated
from level 1 evidence;
C: guideline based on level 3 evidence (descriptive study) or
extrapolated from level 1 or 2 evidence;
D: guideline based on level 4 evidence (expert opinion) or extrap-
olated from level 1, 2, or 3 evidence.
.1. General principles
1) Spondyloarthritis (SpA) is a potentially severe and disabling
chronic illness characterized by a variety of manifestations.
The management of patients with spondyloarthritis should be
coordinated by a rheumatologist, usually in connection with a
multidisciplinary team, in collaboration with the primary care
physician (C) (10).
Spondyloarthritis is a potentially severe disease associated
with a decrease in life expectancy [20,21]. Although the clini-
cal presentation shows extraordinary variability across patients,
all the most common manifestations – inﬂammatory back pain,
peripheral arthritis, and extraarticular signs – are incapacitating
symptoms responsible for pain, temporary or permanent func-
tional impairments [22], and adverse effects on everyday life (e.g.,
asthenia and reactive depression) [23]. Consequently, spondy-
loarthritis requires a multidisciplinary approach involving various
physicians and other healthcare professionals whose work is coor-
dinated by the rheumatologist and conducted in collaboration
with the primary care physician as part of the usual chain of
care.
2) The objectives in patients with spondyloarthritis are to improve
the quality of life; control the symptoms and inﬂammation; pre-
vent structural damage, particularly in forms with peripheral
arthritis; and preserve or restore functional capabilities, self-
sufﬁciency, and social participation (D) (10).
The overall management should ensure the control of all the
dimensions of the disease.
3) The treatment rests on medical decisions shared with the
patient (D) (9,8).
4) The optimal management consists of a combination of pharma-
cological and non-pharmacological means (D) (10).
5) The diagnosis should be established and the management initi-
ated as early as possible (C) (9,7).
Although early disease management has not been proven to
ameliorate the long-term outcomes of patients with spondy-
loarthritis, several lines of evidence suggest beneﬁts from early
diagnostic conﬁrmation and prompt treatment initiation. The
achievement of optimal symptom relief and initiation of the non-
pharmacological components of the management strategy cannot
be started until a deﬁnite diagnosis is made. The mean time from
symptom onset to the diagnosis of spondyloarthritis is still 7 years
[23]. Furthermore, a longer time to diagnosis is associated with
excess mortality in ankylosing spondylitis [21].
.2. Management strategy
6) The goal of management should be to achieve a clinical remis-
sion or a low level of disease activity, as assessed based on
the various components of the illness (axial, peripheral, and
extraarticular manifestations) and on the co-morbidities. Close
monitoring of the patient by the rheumatologist until this goal Spine 81 (2014) 6–14
is achieved may  be required. Once the goal is achieved, regular
individualized follow-up should be provided to ensure that it is
maintained (D) (9,7).
The various therapeutic tools available to the physician and
patient to control disease activity provide major beneﬁts in most
situations and, consequently, ambitious goals should be set. As
with other chronic illnesses, a reasonable treatment objective is
the achievement of a remission or at least of a low level of disease
activity, in compliance with the recent European “treat-to-target”
recommendations [11]. At present, there is no deﬁnition or set of
operational and universally accepted criteria for disease remission
in the various phenotypic forms of spondyloarthritis. To ﬁll this
gap, the deﬁnition of a partial remission developed by the ASAS
for therapeutic trials of NSAIDs [15] or the ASDAS activity cut-offs
(with a score lower than 1.3 deﬁning inactive disease) can be used
[24].
There is no evidence to date to support the use of imaging studies
(most notably MRI) for patient follow-up. The relevance of MRI to
patient follow-up is unknown. The initial treatment phase, during
the period that surrounds and immediately follows the diagnos-
tic workup, requires closely spaced follow-up evaluations to assess
the full range of manifestations and their impact on the patient, the
course under treatment and possible need for treatment adjust-
ments, and the tolerance of the treatment.
7) Smoking is associated with increased disease activity and sever-
ity, and smoking cessation can therefore be expected to beneﬁt the
course of the disease, in addition to improving general health (C)
(9,3).
The adverse effects of smoking in terms of cardiovascular dis-
ease, lung disease, and malignancies are well established. In
addition, smoking has been demonstrated to adversely affect the
course of spondyloarthritis (disease activity, Health Assessment
Questionnaire [HAQ] scores, and radiographic progression were
worse in smokers than in non-smokers with SpA) [25]. These
effects constitute an additional argument in support of smoking
cessation in patients with spondyloarthritis.
8) The rheumatologist should evaluate the disease by investigat-
ing the various domains involved (disease activity, dependency
on anti-inﬂammatory drugs, and disease severity [inﬂammatory
hip disease, functional impairments, incapacitating extraarticular
manifestations, and structural damage]) and assessing the course
over time (D) (9,5).
No validated deﬁnitions or criteria for spondyloarthritis are
available to date. Marked and persistent inﬂammatory activity and
failure to respond to treatments may  provide orientation.
In the opinion of the task force, markers for disease sever-
ity include a high level of disease activity that persists despite
treatment, a need for continuous maximal dose NSAID ther-
apy to control the symptoms, severe functional impairments (as
shown by the BASFI, HAQ score, and difﬁculties at work and with
social activities), the existence and course of structural damage
(particularly at peripheral sites), inﬂammatory hip disease, and
severe extraarticular manifestations (severe recurrent acute ante-
rior uveitis and involvement of the heart and lungs). These markers
are similar to the items listed in the guide of the French National
Authority for Health (Haute Autorité de santé [HAS]) for obtaining
full reimbursement of healthcare costs (Table 2).
The predictors of severe outcomes reported by Amor in 1994 can
be used also:
• inﬂammatory hip disease,
• erythrocyte sedimentation rate > 30 mm,
• poor response to NSAIDs,
• range-of-motion limitation at the lumbar spine,
• “sausage” ﬁnger or toe (dactylitis),
• oligoarthritis,
• and onset ≤ 16 years of age,
D. Wendling et al. / Joint Bone
Table  2
Severity of spondyloarthritis according to the guide issued by the French National
Authority for Health (Haute Autorité de santé [HAS]; Guide ALD no 7, Spondy-
larthrite grave, HAS/Service des bonnes pratiques professionnelles/December 2008)
(www.has-sante.fr).
Spondyloarthritis is classiﬁed as severe if any of the following criteria is met
Presence of a clearly severe manifestation, such as
Destructive arthritis, particularly involving the hip
Concomitant severe extraarticular manifestations, such as
Severe chronic inﬂammatory bowel disease (IBD)
Recurrent uveitis
Or severe spondyloarthritis-related heart disease (aortic or mitral
valve disease, myocardiopathy, pericarditis, atrioventricular conduction
disorder)
Any  of the following ﬁndings present by physician examination on at
least two occasions (3 months apart), despite NSAID therapy in the
maximal recommended or tolerated dosage
Concomitant inﬂammation of more than three joints
Active spondyloarthritis with a BASDAI > 4 on a 0–10 scale
Or  major spondyloarthritis-related functional impairment (in
7particular, BASFI > 4 on a 0–10 scale)
Continuous NSAID therapy in the maximal recommended or tolerated
dosage needed to control the symptoms
• absence of all these items predicts favorable disease outcomes.
9) Follow-up intervals and modalities should be individualized
depending on the presentation, course and treatment of the
disease. Follow-up should include physician visits, the use of self-
evaluation tools, and investigations. At least one tool for evaluating
disease activity must be used. Access to the rheumatologist or to
other specialists should be facilitated when patients experience
intercurrent events (ﬂare of joint disease, extraarticular manifes-
tations, infectious diseases, life project. . .)  (D) (9,5).
The presentation and activity of the disease vary over time in
a given patient, and predicting the course of the disease is difﬁ-
cult. This fact, together with the broad range of drugs available
for treating spondyloarthritis, precludes the deﬁnition of opti-
mal  follow-up intervals or modalities applicable to all patients.
Nevertheless, the chronic nature of spondyloarthritis warrants a
routine minimal follow-up, for instance, once a year, to evaluate
the course of the disease, detect any complications or new man-
ifestations, and evaluate healthcare service utilization; follow-up
should be adjusted to the symptoms and disease progression.
Involvement of axial and/or peripheral joints requires the use of
an appropriate tool for evaluating the initial status and changes
over time; this tool should be selected among those available to
date [15]. In patients with axial involvement, the BASDAI (associ-
ated with C-reactive protein level) and/or ASDAS should be used
to measure disease activity and the BASFI to assess the functional
impact. In patients with predominant or concomitant peripheral
involvement, preference should be given to the tender and swollen
joint counts and to activity indicators, such as the DAS; in psori-
atic arthritis, the PASDAS and PsARC can be used. In the event
of extraarticular manifestations, speciﬁc tools may  be helpful.
According to the speciﬁc nature of the manifestations experienced
by the patient, access to the specialist who is in the best position
to provide appropriate care should be facilitated, depending not
only on the symptoms (e.g., pain due to arthritis or diarrhea due
to a bowel ﬂare), but also on the potential severity of the manifes-
tations (e.g., risk of adhesions or permanent vision loss due to the
delayed treatment of acute anterior uveitis).
.3. Non-pharmacological management
10) Information, health education, and therapeutic education are
integral components of the management of patients with spondy-
loarthritis (C) (9,8).
In an open-label prospective study, a 4-day therapeutic
education program (information classes, individual and group Spine 81 (2014) 6–14 9
physiotherapy sessions, and discussion) signiﬁcantly improved
both knowledge about the disease and motion range of the hips
and spine [26].
In severe forms, in compliance with French regulations,
the primary care physician can request full coverage of all
spondyloarthritis-related healthcare costs by the statutory health
insurance system. Other measures can be taken according to
French legislation relevant to disability compensation and occu-
pational medicine.
11) Patient organizations or organizations that focus on health
and/or assistance may  be of help (D) (9,4).
12) Although home exercises, most notably home programs, are
effective, physical therapy with supervised exercises, particu-
larly in a pool, as individual or group sessions, should be given
preference given its greater effectiveness in axial forms of spondy-
loarthritis (B) (9,1).
This recommendation is particularly relevant to patients with
axial involvement as assessed clinically (motion range limitation)
or radiographically.
Recent publications on this topic [27–33] conﬁrm the beneﬁcial
effects of rehabilitation therapy and self-rehabilitation programs
on indices measuring disease activity and function (BASDAI and
BASFI). For instance, a randomized controlled trial in 62 patients
with ankylosing spondylitis in Italy compared rehabilitation ther-
apy (12 sessions) plus two  therapeutic education sessions to
therapeutic education alone and to a control group. Rehabilitation
therapy was associated with signiﬁcantly greater improvements in
the BASDAI, motion ranges, and BASFI, which persisted 6 months
later [33].
13) The extraarticular manifestations (psoriasis, uveitis, chronic
inﬂammatory bowel disease) should be managed in collaboration
with the appropriate specialists (D) (9,5).
The treatment decisions, follow-up, and dosage adjustments of
certain speciﬁc drugs, as well as the evaluation of certain disease
manifestations (gastrointestinal and ophthalmological in particu-
lar) require the involvement of appropriate specialists to optimize
disease control and obtain the best possible long-term outcomes.
14) As part of the follow-up of this chronic disease, an important
task for the rheumatologist is to ensure that appropriate screening
and management of co-morbidities are provided, including for
osteoporosis, in compliance with current recommendations (D)
(9,2).
Attention should be directed to the development of co-
morbidities in patients with spondyloarthritis, as is the case
with all chronic inﬂammatory diseases. The spondyloarthritis
may  worsen the co-morbidities (particularly cardiovascular co-
morbidities), which also limit the use of various drug classes [34].
Cardiovascular co-morbidities deserve special attention, as
well as osteoporosis, whose prevalence is increased in patients
with spondyloarthritis [35–38]. The overall management of co-
morbidities should be conducted in collaboration with the primary
care physician.
7.4. Treatment with conventional medications
15) In the absence of contraindications, NSAIDs constitute the ﬁrst-
line pharmacological treatment of symptomatic spondyloarthritis
(A) (10).
In most patients, NSAID therapy effectively controls the joint
symptoms and signs of spondyloarthritis [39,40]. NSAIDs have
non-signiﬁcant effects on laboratory markers for inﬂammation
[39]; in contrast, various results suggest a beneﬁcial effect on
axial structural damage [41]. When NSAIDs are contraindicated,
analgesics and physical therapy should be given preference to the
ﬁrst-line treatment. The response to a given NSAID varies across
1 t Bone0 D. Wendling et al. / Join
individuals, and several NSAIDs should therefore be tried before
concluding that this drug class is not effective.
16) The NSAID regimen should be tailored to each individual
patient, and the lowest dosage and duration ensuring symptom
control should be used. When selecting the NSAID, the risks of
adverse cardiovascular, gastrointestinal, and renal effects should
be among the factors taken into consideration (C) (9,7).
Before initiating NSAID therapy, the cardiovascular, gastroin-
testinal, and renal risk factors should be assessed. The risk proﬁle
varies across NSAIDs and, consequently, the presence of spe-
ciﬁc patient characteristics should be taken into account when
selecting the NSAID. For instance, a COX2 inhibitor should be
given preference in patients with gastrointestinal risk factors and
naproxen in those with cardiovascular risk factors. All patients
should be monitored carefully and regularly for adverse effects.
Given the risks associated with continuous full-dose NSAID ther-
apy, the lowest dose that ensures disease control should be sought
[42,43].
17) Analgesics can be used in patients with residual pain despite
NSAID therapy and in patients with failure of, contraindications
to, or intolerance to NSAIDs (D) (9,8).
No data on analgesic treatments in spondyloarthritis have been
published recently [44].
18) Local glucocorticoid injections at symptomatic sites (most
notably sites of arthritis or enthesitis) can be considered (D) (9,8).
The evidentiary basis for this guideline is described in the
previous recommendations. The only recent data come from a
non-randomized study comparing locally injected betamethasone
(n = 7) to locally injected etanercept in patients with refractory
enthesitis. Signiﬁcant improvements occurred in both groups with
no signiﬁcant between group difference after 12 weeks [45].
19) In general, systemic glucocorticoid therapy is not warran-
ted for treating the axial manifestations of spondyloarthritis
(D) (9,7).
Given the numerous and potentially severe adverse effects of
systemic glucocorticoid therapy, together with the paucity of
published data, this treatment is not warranted for the axial
manifestations of spondyloarthritis. The only therapeutic trial
of systemic glucocorticoid therapy included a limited number
of patients (n = 39) who had an inadequate response to NSAID
therapy; in addition, the trial evaluated high dosages (50 mg/d
versus 20 mg/d versus placebo) [46] given for only 2 weeks. Conse-
quently, the improvements recorded with the higher dose cannot
be construed as supporting the widespread use of this treat-
ment. However, systemic glucocorticoid therapy may  deserve
consideration when the peripheral joint manifestations are not
satisfactorily controlled, in the absence of effective or feasi-
ble treatment options (e.g., in patients with contraindications
to TNF antagonist therapy) or in unusual situations (e.g., ﬂare
associated with inﬂammatory bowel disease). In these cases,
the lowest possible dosage of systemic glucocorticoid must be
used.
20) To date, there is no indication for conventional disease-
modifying antirheumatic drugs ([DMARDs], methotrexate,
leﬂunomide, and sulfasalazine) to treat isolated axial manifesta-
tions or enthesitis (C) (9,3).
Since the publication of the previous recommendations, no
studies have produced evidence that conventional DMARDs are
effective on the axial manifestations. For methotrexate, a Cochrane
review published in 2013 [47] found no new studies since 2007.
Two randomized trials from Germany compared etanercept and
sulfasalazine in patients with axial spondyloarthritis [48–50];
etanercept was superior over sulfasalazine for the various out-
come measures studied (ASAS20, ASAS 40, and partial remission).
The absence of a placebo group precluded an evaluation of the
effects of sulfasalazine. Spine 81 (2014) 6–14
21) The use of conventional DMARDs (methotrexate, leﬂunomide,
and sulfasalazine) can be considered in patients with peripheral
arthritis that fails to respond to symptomatic therapy (D) (9,8).
There is little or no scientiﬁc evidence on this point [51,52].
Nevertheless, clinical experience supports a beneﬁcial effect
of conventional DMARDs (methotrexate, leﬂunomide, and sul-
fasalazine), whose use can be considered in patients with
peripheral arthritis that is inadequately controlled by NSAIDs
and/or local glucocorticoid injections. The DMARD should be
selected on a case-by-case basis, according to the patient’s pro-
ﬁle. For instance, preference should be given to methotrexate
in patients with cutaneous psoriasis. In France, leﬂunomide and
methotrexate are licensed for use in psoriatic arthritis. No stud-
ies have assessed the potential structural effects of conventional
DMARDs on peripheral joints. Some conventional DMARDs (sul-
fasalazine, methotrexate) may  also improve the extraarticular
manifestations (uveitis, bowel disease). Experts agree that con-
ventional DMARDs are not indicated in patients with isolated
entheseal involvement, a situation about which no scientiﬁc evi-
dence is available [5,7,8].
7.5. Biologic agents
22) TNF antagonist therapy should be offered to patients with
persistent disease activity despite conventional treatment, accord-
ing to the recommendations shown in Fig. 1 (D) (9,8).
Fig. 1 recapitulates the recommendations for using TNF
antagonists according to the clinical presentation (phenotype),
when the conventional treatment fails or induces an inadequate
response with persistent disease activity and objective evidence of
inﬂammation. When objective evidence of inﬂammation is lack-
ing, the opinion of experts is taken into account. The presence
and progression of extraarticular manifestations should also be
taken into consideration. The generally applicable indications can
be modulated according to a number of factors, such as the amount
of NSAIDs required on a daily basis, in the light of the risk/beneﬁt
ratio for each treatment option.
An inadequate response to NSAID therapy can be deﬁned either
as persistence of symptoms despite maximal dosage NSAID ther-
apy or as persistent disease activity with a BASDAI ≥ 4/10 or an
ASDAS ≥ 2.1 during NSAID therapy.
The initiation and follow-up of TNF antagonist therapy should
be conducted according to the current recommendations and
practice guidelines: overall management of TNF antagonists as
described in the CRI fact sheets CRI [10] and recommendations
issued by the SFR/CRI/HAS [53].
A number of factors that predict a good response to TNF
antagonist therapy have been identiﬁed in patients with spondy-
loarthritis [54]: systemic evidence of inﬂammation at baseline
(CRP), high values of disease activity and functional impair-
ment scores, young age, presence of HLA-B27, peripheral arthritis,
and male gender are independently associated with a treatment
response and with treatment continuation. In contrast, obesity is
associated with a poorer response to TNF antagonists in both
ankylosing spondylitis [55] and psoriatic arthritis [56]. The pres-
ence of one or more of these factors may  inﬂuence the decision to
start TNF antagonist therapy. Nevertheless, the absence of fac-
tors associated with a good response does not warrant a decision
against TNF antagonist therapy in patients who meet criteria for
this treatment.
All the TNF antagonists available to date for use in spondy-
loarthritis have been proven effective in various forms of the
disease [17,57–59]. TNF antagonist therapy improved the symp-
toms and signs of spondyloarthritis, quality of life, productivity,
and bone mineral density. The safety proﬁle of TNF antagonists
in spondyloarthritis is similar to the overall safety proﬁle of these
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drugs [10,53]. It is worth noting that some patients may  expe-
rience paradoxical effects [57], deﬁned as the occurrence during
TNF antagonist therapy of manifestations that are among the
indications for TNF antagonists (e.g., uveitis, psoriasis, or de
novo Crohn’s disease at a time when the rheumatic manifesta-
tions of spondyloarthritis are well controlled by TNF antagonist
therapy).
Routine prescription of a conventional DMARD in combination
with the TNF antagonist is unnecessary [60]. Pivotal studies have
established that single-drug therapy with a TNF antagonist is
effective, and there is no evidence to date that further beneﬁts can
be obtained by adding a conventional DMARD to a TNF antago-
nist in patients with spondyloarthritis, including psoriatic arthritis
[61]. Whether combined treatment with a conventional DMARD
may  help to diminish the immunogenicity of TNF antagonists
(most notably the monoclonal antibodies) is a controversial point
that is currently under investigation.
Patients may  develop an immune response against biological
agents (anti-drug antibodies, ADAb). Such a response is more
common with monoclonal antibodies against TNF. It is often
accompanied with an increased frequency of adverse reactions
(particularly infusion reactions) and with diminished effective-
ness [62].
In every case, the individual risk/beneﬁt ratio should be taken
into account when making the treatment decision.
23) The response to TNF antagonist therapy should be evaluated
after at least 3 months, using objective measures of disease activity
(D) (9,1).
Examples of such measures are the decrease in NSAID consump-
tion (ASAS-NSAID score) [63] or the percentage of days without
NSAID use; a BASDAI decrease by 50% or by 2 points; an ASDAS
decrease by more than 1.1 point [24] or an ASAS 20 or ASAS 40
response or an ASAS partial remission [15]; and the DAS-based
EULAR response in patients with peripheral arthritis. Tests to
monitor the initial systemic inﬂammation can also be included
in the evaluation. Effectiveness is assessed based on the symp-
toms and signs. In everyday practice, follow-up imaging studies
(e.g., MRI  or radiographs) are unnecessary for evaluating the treat-
ment response. At present, the possibility that TNF antagonists antagonist therapy.
may  induce a radiographic structural response rests on a limited
number of studies [64].
Effects on the extraarticular manifestations should be recorded.
In addition to the clinical response, safety data should be taken
into account when deciding whether to continue the treatment.
24) In the event of primary or secondary lack of effectiveness of
a TNF antagonist, there is no proof to date that increasing the
dosage is beneﬁcial. After reappraising the diagnosis of spondy-
loarthritis and ruling out a differential diagnosis or complication
of the disease, a switch to another TNF antagonist deserves con-
sideration (D) (9,7).
Switching to a second TNF antagonist may be beneﬁcial,
in particular in the event of escape phenomenon, primary
ineffectiveness, or intolerance to a ﬁrst TNF antagonist
(C) (9,7).
Several studies found no advantages to high-dose etanercept
therapy, including the PRESTA trial in psoriatic arthritis [65] and
LOADET in ankylosing spondylitis [66], in which doubling the dose
conferred no beneﬁts compared to the standard dose at treatment
initiation.
In this situation, monitoring the serum levels of the biological
agent and, if appropriate, performing tests for antibodies against
the biological agent, may  provide a more accurate analysis and
help to adjust the dosage [67].
In non-responders, an evaluation should be performed to deter-
mine that the symptoms are related to the inﬂammatory activity
of the spondyloarthritis.
The option of switching to another TNF antagonist rests on
observational data from cohorts and registries for axial spondy-
loarthritis [68,69] and psoriatic arthritis [70]. In these studies,
the continuation rate of a second TNF antagonist was close to,
but lower than, that of the ﬁrst-line TNF antagonist; in contrast,
lower continuation rates were found for the third TNF antagonist.
25) In the event of a disease remission or low level of activity sus-
tained for at least 3 to 6 months under TNF antagonist therapy,
a gradual increase in the dosing interval or decrease in the drug
dosage can be considered (C) (9,6).
Several studies show that the dosing interval can be increased
or the dosage reduced in the event of a stable prolonged remission
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[71–73]. This adjustment decreases the cost of treatment. It should
be conducted gradually and under clinical supervision, given the
risk of a disease ﬂare during the decrease in drug exposure; if a
ﬂare occurs, the patient should be returned to the previous dosing
interval or dosage.
26) There is no evidence to support differences across TNF
antagonists regarding effectiveness on the axial or peripheral
manifestations/enthesitis. In patients with chronic inﬂammatory
bowel disease (IBD), there is a difference in effectiveness on
the gastrointestinal manifestations, which should be taken into
account. (D)(9.7).
No head-to-head comparisons of various TNF antagonists have
been conducted in patients with spondyloarthritis. Consequently,
no data are available for establishing a hierarchy of TNF antag-
onists. Among TNF antagonists, only monoclonal antibodies to
TNF have been proven effective on the manifestations of inﬂam-
matory bowel disease.
27) There is no evidence to date to support the use of biological
agents other than TNF antagonists in patients with axial spondy-
loarthritis (D) (9,6).
In patients who fail treatment with conventional DMARDs and
TNF antagonists, no treatment options exist [74]. Abatacept
has not been proven effective [75]; rituximab is not effective in
patients having failed TNF antagonist therapy and remains to
be evaluated in biotherapy-naive patients with peripheral joint
manifestations [76–78]. Retrospective data on IL-6-antagonists
are inconclusive [79] and controlled studies show no effect [80].
Options currently under investigation for spondyloarthritis and
psoriatic arthritis include the anti-IL-17 secukinumab [81,82], the
anti-IL-23 ustekinumab [83], and apremilast [84,85]. Ustekinumab
(anti-p40 IL-12/23) is licensed for use in patients with psoriatic
arthritis and an inadequate response to the conventional treat-
ment.
.6. Surgical treatments
28) Total arthroplasty can be offered to patients of any age who
have structural joint damage responsible for refractory pain and
severe functional impairments (D) (10).
This practice guideline applies chieﬂy to the hip [86]. The risk
of subsequent development of a periprosthetic ossiﬁcation should
be evaluated.
29) In exceedingly rare cases, spinal osteotomy deserves consider-
ation to correct severe incapacitating spinal deformities (D) (9,2).
The indications for this procedure have become exceed-
ingly rare. The goal is to restore the horizontal line of vision.
Useful functional improvements can be obtained but the pro-
cedure is challenging to perform and associated with speciﬁc
complications (intubation difﬁculties, vascular and neurological
complications).
30) In patients with a spinal fracture that occurred recently or
has failed to heal, advice from a spinal surgeon should be sought.
In the event of a signiﬁcant and/or abrupt change in the symp-
toms, causes other than inﬂammation, such as a spinal fracture,
should be considered and sought using appropriate investigations,
including imaging studies (D) (9,7);
Fractures in a fused spinal segment carry a risk of instability,
which can induce neurological complications. The possible pres-
ence of osteoporosis in patients with spondyloarthritis should be
borne in mind. Commonplace osteoporotic vertebral fractures are
low-risk events that should be distinguished from more speciﬁc
fractures in a fused spinal segment with a fracture line through a
disk or vertebral body.
Close attention should be given to patient follow-up, and during
follow-up the symptoms should be analyzed carefully. Spine 81 (2014) 6–14
8. Research agenda
Several unresolved issues regarding the management of patients
with spondyloarthritis were identiﬁed by the task force:
• deﬁnition and criteria of remission in spondyloarthritis (depend-
ing on the phenotypic form);
• deﬁnition and criteria of disease ﬂare (depending on the pheno-
typic form);
• deﬁnition and criteria of severity of spondyloarthritis;
• role for the structural damage, particularly to the axial skeleton,
in the evaluation of the disease and treatment response;
• role for biological agent assays and tests for antibodies to biolog-
ical agents in the adjustment of the treatment regimen.
These practice guidelines will now be disseminated. In 2 years
(2016), the task force plans to evaluate their impact and to decide,
based on the availability of new data, on a revision date.
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